Positive News Sentiment NASDAQ:OCUL Ocular Therapeutix - OCUL Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $5.07 -0.07 (-1.36%) (As of 03/28/2023 12:00 AM ET) Add Compare Share Share Today's Range$4.94▼$5.2950-Day Range$3.87▼$6.2752-Week Range$2.57▼$6.53Volume640,329 shsAverage Volume1.52 million shsMarket Capitalization$392.97 millionP/E RatioN/ADividend YieldN/APrice Target$11.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Ocular Therapeutix MarketRank™ ForecastAnalyst RatingBuy3.33 Rating ScoreUpside/Downside126.8% Upside$11.50 Price TargetShort InterestBearish5.78% of Shares Sold ShortDividend StrengthN/ASustainability-2.01Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$161,777 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.03) to ($0.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.27 out of 5 starsMedical Sector316th out of 1,002 stocksPharmaceutical Preparations Industry136th out of 488 stocks 3.7 Analyst's Opinion Consensus RatingOcular Therapeutix has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.50, Ocular Therapeutix has a forecasted upside of 126.8% from its current price of $5.07.Amount of Analyst CoverageOcular Therapeutix has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.78% of the outstanding shares of Ocular Therapeutix have been sold short.Short Interest Ratio / Days to CoverOcular Therapeutix has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ocular Therapeutix has recently increased by 12.56%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOcular Therapeutix does not currently pay a dividend.Dividend GrowthOcular Therapeutix does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOcular Therapeutix has received a 57.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Ophthalmologicals (S01)" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Ocular Therapeutix is -2.01. Previous Next 2.7 News and Social Media Coverage News SentimentOcular Therapeutix has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Ocular Therapeutix this week, compared to 2 articles on an average week.Search InterestOnly 11 people have searched for OCUL on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ocular Therapeutix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $161,777.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of Ocular Therapeutix is held by insiders.Percentage Held by Institutions55.40% of the stock of Ocular Therapeutix is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ocular Therapeutix are expected to grow in the coming year, from ($1.03) to ($0.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ocular Therapeutix is -4.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ocular Therapeutix is -4.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOcular Therapeutix has a P/B Ratio of 11.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ocular Therapeutix (NASDAQ:OCUL) StockOcular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.Read More Receive OCUL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter. Email Address OCUL Stock News HeadlinesMarch 16, 2023 | markets.businessinsider.comJMP Securities Keeps Their Buy Rating on Aura Biosciences Inc (AURA)March 11, 2023 | finance.yahoo.comDowngrade: Here's How Analysts See Ocular Therapeutix, Inc. (NASDAQ:OCUL) Performing In The Near TermMarch 28, 2023 | The Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.March 9, 2023 | msn.comLooking Into Ocular Therapeutix's Return On Capital EmployedMarch 8, 2023 | finance.yahoo.comOcular Therapeutix Full Year 2022 Earnings: Revenues Beat Expectations, EPS LagsMarch 8, 2023 | finance.yahoo.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Q4 2022 Earnings Call TranscriptMarch 8, 2023 | finance.yahoo.comWhat Makes Ocular Therapeutix (OCUL) a Good Fit for 'Trend Investing'March 8, 2023 | msn.comThe Latest Analyst Ratings for Ocular TherapeutixMarch 28, 2023 | Porter & Company (Ad)A strange force is brewing…An economic force with the potential to be bigger than the 1880s railroad boom, the 1920s automobile boom, the baby boom of the 1960s, or the Dotcom boom of the ‘90s. And while Biden has nothing to do with it… he’ll take full credit. March 7, 2023 | finance.yahoo.comQ4 2022 Ocular Therapeutix Inc Earnings CallMarch 6, 2023 | finance.yahoo.comOcular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue EstimatesMarch 6, 2023 | msn.comOcular Therapeutix Q4 GAAP EPS, revenue beats, guidance below consensusMarch 6, 2023 | finance.yahoo.comOcular Therapeutix™ Provides Fourth Quarter and Year-End 2022 Results and Corporate UpdateFebruary 28, 2023 | finance.yahoo.comOcular Therapeutix™ to Present at Cowen’s 43rd Annual Healthcare ConferenceFebruary 26, 2023 | marketwatch.comGlobal Ocular Drug Delivery Technology Market Growth, Size and Manufacturers Analysis Research Report and Forecast 2023-2030 By VMReportsFebruary 26, 2023 | marketwatch.comGlobal Ocular Drug Delivery Market Research Report 2023 by Product, Application, End-users, Region And Global Forecast to 2030 By VMReportsFebruary 22, 2023 | marketwatch.comHydrogel Market In 2023 By In-depth Analysis of Revenue Forecast and Competitive Landscape 2028February 22, 2023 | marketwatch.comGlobal Ocular Drug Delivery Market International Competition and Emerging Business Opportunities to 2028February 21, 2023 | finance.yahoo.comOcular Therapeutix™ To Report Fourth Quarter and Year-End 2022 Financial ResultsFebruary 16, 2023 | finance.yahoo.comWhy Shares of Ocular Therapeutix Jumped This WeekFebruary 14, 2023 | marketwatch.comOcular Pain Market : Future Scope, Demand, Perceptive and Comprehensive Analysis By 2028February 13, 2023 | markets.businessinsider.comBerenberg Bank Keeps Their Buy Rating on Ocular Therapeutix (OCUL)February 13, 2023 | msn.comOcular Soars after Positive Interim DataFebruary 13, 2023 | msn.com4 stocks to watch on Monday: Bally's, Ocular Therapeutix and moreFebruary 13, 2023 | marketwatch.comOcular Therapeutix Shares Up 14% on OTX-TKI Retinal Treatment DataFebruary 13, 2023 | msn.comOcular stock rises ~15% as eye drug implant shows promise in ongoing phase 1 trialFebruary 11, 2023 | finance.yahoo.comOcular Therapeutix™ Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMDSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive OCUL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter. Email Address OCUL Company Calendar Last Earnings11/08/2021Today3/28/2023Next Earnings (Estimated)5/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OCUL CUSIPN/A CIK1393434 Webwww.ocutx.com Phone(781) 357-4000Fax781-357-4001Employees228Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.50 High Stock Price Forecast$14.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+126.8%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,040,000.00 Net Margins-137.95% Pretax Margin-137.95% Return on Equity-127.95% Return on Assets-43.48% Debt Debt-to-Equity Ratio1.53 Current Ratio4.13 Quick Ratio4.07 Sales & Book Value Annual Sales$51.49 million Price / Sales7.63 Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book11.02Miscellaneous Outstanding Shares77,509,000Free Float73,789,000Market Cap$392.97 million OptionableOptionable Beta1.28 Key ExecutivesAntony MattessichPresident, Chief Executive Officer & DirectorDonald NotmanChief Financial OfficerPeter JarrettChief Scientific OfficerRabia Gurses OzdenChief Medical OfficerKaren-Leigh EdwardsSenior Vice President-Technical OperationsKey CompetitorsSIGA TechnologiesNASDAQ:SIGAVanda PharmaceuticalsNASDAQ:VNDAKaryopharm TherapeuticsNASDAQ:KPTIPepGenNASDAQ:PEPGArcturus TherapeuticsNASDAQ:ARCTView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCSold 14,011 shares on 3/23/2023Ownership: 0.035%Alliancebernstein L.P.Bought 7,100 shares on 2/16/2023Ownership: 0.121%Boothbay Fund Management LLCSold 11,621 shares on 2/15/2023Ownership: 0.046%Jane Street Group LLCBought 4,965 shares on 2/15/2023Ownership: 0.036%Steward Partners Investment Advisory LLCBought 3,500 shares on 2/15/2023Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions OCUL Stock - Frequently Asked Questions Should I buy or sell Ocular Therapeutix stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OCUL shares. View OCUL analyst ratings or view top-rated stocks. What is Ocular Therapeutix's stock price forecast for 2023? 3 equities research analysts have issued 1-year price objectives for Ocular Therapeutix's shares. Their OCUL share price forecasts range from $10.00 to $14.00. On average, they expect the company's stock price to reach $11.50 in the next twelve months. This suggests a possible upside of 126.8% from the stock's current price. View analysts price targets for OCUL or view top-rated stocks among Wall Street analysts. How have OCUL shares performed in 2023? Ocular Therapeutix's stock was trading at $2.81 at the beginning of 2023. Since then, OCUL shares have increased by 80.4% and is now trading at $5.07. View the best growth stocks for 2023 here. When is Ocular Therapeutix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. View our OCUL earnings forecast. How were Ocular Therapeutix's earnings last quarter? Ocular Therapeutix, Inc. (NASDAQ:OCUL) issued its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.03. The biopharmaceutical company had revenue of $12.15 million for the quarter, compared to analyst estimates of $12.13 million. Ocular Therapeutix had a negative trailing twelve-month return on equity of 127.95% and a negative net margin of 137.95%. During the same quarter in the prior year, the company posted ($0.17) EPS. What ETFs hold Ocular Therapeutix's stock? ETFs with the largest weight of Ocular Therapeutix (NASDAQ:OCUL) stock in their portfolio include Invesco Raymond James SB-1 Equity ETF (RYJ), SPDR S&P Pharmaceuticals ETF (XPH), Principal Healthcare Innovators ETF (BTEC) and Invesco Nasdaq Biotechnology ETF (IBBQ) and What guidance has Ocular Therapeutix issued on next quarter's earnings? Ocular Therapeutix updated its FY 2023 earnings guidance on Monday, March, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $55.00 million-$60.00 million, compared to the consensus revenue estimate of $69.98 million. What other stocks do shareholders of Ocular Therapeutix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX). What is Ocular Therapeutix's stock symbol? Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL." Who are Ocular Therapeutix's major shareholders? Ocular Therapeutix's stock is owned by a variety of institutional and retail investors. Top institutional investors include Summer Road LLC (7.95%), Opaleye Management Inc. (7.89%), Deltec Asset Management LLC (2.41%), Geode Capital Management LLC (1.83%), Emerald Advisers LLC (1.25%) and Emerald Mutual Fund Advisers Trust (0.88%). Insiders that own company stock include Antony C Mattessich, Christopher G White, Donald Notman, Philip C Strassburger, Richard L Md Lindstrom and Summer Road Llc. View institutional ownership trends. How do I buy shares of Ocular Therapeutix? Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ocular Therapeutix's stock price today? One share of OCUL stock can currently be purchased for approximately $5.07. How much money does Ocular Therapeutix make? Ocular Therapeutix (NASDAQ:OCUL) has a market capitalization of $392.97 million and generates $51.49 million in revenue each year. The biopharmaceutical company earns $-71,040,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. How many employees does Ocular Therapeutix have? The company employs 228 workers across the globe. How can I contact Ocular Therapeutix? Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The official website for the company is www.ocutx.com. The biopharmaceutical company can be reached via phone at (781) 357-4000, via email at chris.brinzey@westwicke.com, or via fax at 781-357-4001. This page (NASDAQ:OCUL) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.